Bristol/ImClone's Erbitux Clears FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Erbitux is indicated in treatment of EGFR-expressing, metastatic colorectal carcinoma for use in combination with irinotecan or as monotherapy.